In addition, we present ELISPOT data providing preliminary evidence of selective mutant peptide recognition by sorted CD8+ tumor-infiltrating lymphocyte (TIL) rapidly expanded from 4 patients. The gene discussed is CD8A; the disease is neoplasm.